ABOUT: Good Morning, It’s Friday Jan. 06, 2012, I’m Lynn Lumpkin with CRWENewswire Stocks In Action. BioDelivery Sciences International Inc - BDSI - reported the signing of a worldwide license and development agreement with Endo Pharmaceuticals for the exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain. In aggregate, the agreement is worth up to $180 million to BioDelivery Sciences if all milestones are met. For the third quarter ended November 30, 2011, AZZ inc - AZZ - posted revenues of $116.5 million, a 13% increase year over year. and lastly; The Greenbrier Companies - GBX - reported Revenue of $398.2 million for the first quarter of 2012, double the Revenue realized in the same period the prior year. Thank you for joining me and have a great day! For CRWE Newswire, Stocks In Action, Lynn LumpkinrnrnTHIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY! (Read Full Disclaimer at http://www.crwenewswire.com/disclaimer)rn